If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A Spanish research institution in collaboration with other co-owners have developed chemical derivatives that act selectively against the bacterium Helicobacter pylori, managing to reduce the bacterial load and even eradicate gastric infections caused by it.
Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement.
Derivatives without resistance against gastric infections.
The bacterium Helicobacter pylori (Hp) causes asymptomatic infections in the gastric mucosa that can induce chronic gastritis, ulcers even gastric cáncer. So far, conventional therapies are aggressive and the rate of eradication is decreasing, as Hp is increasingly resistant to such treatment.
Derivatives of benzo [c] [1,2,5]oxadiazol (Figure 1) are antimicrobials that act individually (without combination with other drugs) and selectively, attack a specific enzyme of the bacterium, its flavodoxine. In humans the enzyme is not present, so possible secondary damage is avoided.
The results obtained in mice have been, reduced rates of gastric colonization of Hp and even eradication in up to 60% of mice.
Industrial partner is being sought to collaborate through a patent license agreement. The partner role will be: (i) produce the cells and, (ii) commercialize the cells.
Then main advantages are:
1. New antibiotics without known resistances.
2. Efficacy in resistant strains.
3. Safety: no toxicity at their active concentrations.
4. Low cost synthesis.
5. Bactericidal activity at low concentrations.
6. Current status, in vitro: toxicity in cells and in vivo: both toxicity and efficacy test in mice.
Spanish patent application filed
Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement. The partner role will be: (i) produce the antibiotics and, (ii) commercialize the antibiotics.